ArticleJournal of diabetes research2025
Real-World Evidence on Mobile App-Supported Diabetes Management in Insulin-Treated Patients.
Article in Journal of diabetes research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between a clinical pharmacist-led multimodal remote medication intervention and individualized treatment outcomes in patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2026Article
- Real-World Evidence on Mobile App-Supported Diabetes Management in Insulin-Treated Patients.Journal of diabetes research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Digital health interventions, such as mobile diabetes apps, are aimed at supporting glycemic control. Real-world data (RWD) provide valuable insights into their long-term effectiveness beyond the controlled conditions of randomized trials. Objective: This study evaluates the effectiveness of the mobile diabetes app ESYSTA in improving glycemic control using real-world evidence. Methods: A retrospective analysis of 475 users was conducted to assess HbA1c changes after 6 months of usage and also long-term usage (12 and 15 months). A linear mixed model was used to adjust for confounding factors. Results: After 6 months, ESYSTA users achieved a significant HbA1c reduction of -0.59 (-0.70; -0.48) percentage points compared to baseline, which was maintained for up to 15 months. Users with higher baseline HbA1c showed greater reductions. Seventy-five percent of users tracked their blood glucose values consistently during the whole observation period. Conclusion: These real-world evidence findings demonstrate the effectiveness of a mobile diabetes app in improving glycemic control over an extended period. While statistical adjustments addressed potential biases, missing data remain a challenge. Further research, including controlled studies, is needed to confirm these real-world results and further explore the underlying mechanisms of sustained HbA1c improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.